

ASX ANNOUNCEMENT

5 July 2019

Lapse of Employee Share Options

Melbourne, Australia, 5 July 2019:

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “**Company**”), advises that 500,000 unlisted share options granted pursuant to the Company’s employee option plan have lapsed. The details of these lapsed options are:

Unlisted employee option reference	Exercise price	Options lapsed
GTGAD (expiring 11 December 2021)	\$0.010	500,000
Total		500,000

Accordingly, as at the date of this announcement, there are a total of 38,000,000 outstanding options over shares in the Company.

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company lead products ***GeneType for Breast Cancer*** and ***GeneType for Colorectal Cancer*** are clinically validated risk assessment tests for non-hereditary breast cancer and are first in class.

Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit www.gtglabs.com

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the [Private Securities Litigation Reform Act](#). The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

FOR FURTHER INFORMATION PLEASE CONTACT

Mr Paul Viney
Company Secretary
Genetic Technologies Limited
+61438072616